We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

Fund managers haven’t disclosed any holdings of ATYR yet.

ATYR Hedge Fund Activity: Q1 2026 in Review

111 of the 8,131 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2026, worth a combined $43.7M — down 22% from $55.7M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ATYR positions and 8 closed out — a net gain of 28 holders — while 27 added to existing stakes and 30 trimmed.

The largest buyer was UBS Group, adding an estimated $1.89M. The largest seller was Rosalind Advisors, exiting entirely with an estimated $13.6M sold.

  • 111 institutional investors held aTyr Pharma (ATYR) as of Q1 2026, up from 84 in Q4 2025.
  • Funds reported $43.7M of aTyr Pharma stock for Q1 2026, down 22% quarter-over-quarter.
  • 36 funds opened new aTyr Pharma positions in Q1 2026 and 8 closed out, a net change of +28 holders.
  • The largest aTyr Pharma buyer in Q1 2026 was UBS Group, an estimated $1.89M added.
  • The largest aTyr Pharma seller in Q1 2026 was Rosalind Advisors, an estimated $13.6M sold.

Based on aggregated 13F filings for Q1 2026.